康基醫療(09997.HK)中期純利增加11.9%至2.86億元
格隆匯8月20日丨康基醫療(09997.HK)公吿,截至2024年6月30日止六個月,公司實現人民幣458.4百萬元的收入,相較2023年同期增長13.6%。集團銷售增加主要歸因於一次性產品的銷售增加。
集團報吿期內母公司擁有人應占純利由2023年的人民幣255.5百萬元增加11.9%至2024年的人民幣285.8百萬元。有關增加的主要原因為收入及其他收入及收益增加。集團於報吿期內母公司擁有人應占非《香港財務報吿準則》經調整純利由2023年的人民幣237.2百萬元增加15.9%至2024年的人民幣274.9百萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.